Headcount: 29,000
Year Established: 1916
Revenues: $15,558 (+5%)
Net Income: $1,359 (+5%)
R&D: $3,219 (+14%)

Australia’s prominent specialty biopharma company is comprised of three core segments: CSL Behring focuses on blood plasma products and gene therapies for bleeding disorders, immunodeficiencies, and neurological conditions; CSL Seqirus manufactures seasonal influenza vaccines; and CSL Vifor specializes in treatments for iron deficiency and nephrology.

CSL previously outlined a restructuring plan in August that included separating its Seqirus influenza vaccine business into a standalone entity, however, to date this appears to be on hold. The company is also planning workforce reductions of up to 15% and the closure of selected plasma collection centers. The separation of Seqirus, together with cost cutting initiatives suggests an effort to simplify operations and refocus capital.

To lead the restructuring and oversee intended Seqirus division, Gordon Naylor was named Chief Executive Officer and Managing Director of CSL in February. Naylor succeeds Paul McKenzie who retired from the position in February.

Manufacturing Expansions

Despite restructuring initiatives, CSL has made significant investments to expand manufacturing capabilities. In December CSL Seqirus opened its cell-based influenza vaccine and antivenom manufacturing facility in Melbourne, expanding its onshore manufacturing capabilities and becoming one of three countries globally with the end-to-end capability to make cell-based flu vaccines. The new facility will replace the existing CSL Seqirus egg-based vaccine manufacturing facility in Parkville, Melbourne. CSL invested over $1 billion to build the digitally enabled facility with contributions from the Victorian Government.

Meanwhile, CSL is investing $1.5 billion to expand its manufacturing facility in Kankakee, IL as part of its growth strategy to expand its U.S. production of plasma-derived therapies for rare and serious diseases and other acute medical issues. Expected to be operational by 2031, the expansion will incorporate CSL’s Horizon 2 manufacturing process, a yield enhancing technology that enables significantly greater production of immunoglobulin. Since 2018, CSL has invested over $3 billion into its U.S. operations.

R&D Alliance

A strategic collaboration with Dutch biotech VarmX BV will support the development of VMX-C001, a treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on Factor Xa direct oral anticoagulants. CSL paid $117 million upfront for an exclusive option to acquire the company. CSL will have the right to exercise the option upon receipt of Phase 3 data. If certain milestones are met VarmX will receive an additional $388 million up to the launch of VMX-C001, which is anticipated in 2029.

Headcount: 32,452
Year Established: 1916
Revenues: $14,744 (+11%)
Net Income: $2,818 (+26%)
R&D expenses: $1,428 (+12%)
*Numbers based on CSL Half Year Results February 2025

Despite the impact of declines in U.S. influenza vaccination rates, demand for CSL’s plasma products is rising and supply is improving. Also, with the recent approval of Andembry, expanding its HAE franchise, CSL’s outlook is progressing.

As one of only a handful of providers of plasma products, sourcing and supply can be a challenge. CSL Behring’s new plasma processing facility in Broadmeadows, Victoria recently began operations, increasing its plasma processing capacity in Australia by nine times. It is now able to handle more than 10 million liters of plasma per year. This helps produce key components for medicines that treat immune disorders, bleeding conditions like hemophilia, and other serious health issues.

In June, the U.S. FDA approved CSL’s Andembry, becoming the only prophylactic Hereditary Angioedema (HAE) treatment targeting Factor XIIa with once-monthly dosing for all patients from the start. Andembry inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks. Additionally, the once-monthly dosing was shown to reduce HAE attacks by a median of more than 99 percent compared to placebo.

This profile references CSL’s 2025 half year results, released February 2025. When looking at CSL’s performance by business, CSL Behring, overseeing biotherapeutics, had the highest revenue of $10.6 billion, up 14% in consistent currency. CSL Behring sales were strong in emerging markets, with solid growth in China, the U.S., and Europe.

CSL’s largest franchise, the immunoglobulin (Ig) portfolio, largely contributed to company growth. Ig revenue reached $3.2 billion, increasing 15% with strong growth recorded across all geographies. Privigen and Intragam increased by 15%, and Hizentra increased by 16%.

The Albumin segment increased by 9% to $672 million in revenue, with strong growth in China. Revenue for CSL’s Hemophilia franchise reached $731 million, an 11% increase. Idelvion remained a market leader with a 6% increase, Hemgenix saw an uptake in acceleration, and Plasma-derived coagulants grew 6%, led by Von Willebrand Factor (VWF).

However, Specialty products sales were down 5% to $921 million, mainly impacted by the loss of a substantial contract for Kcentra, with sales down 20%. In this segment, Haegarda sales grew by 1% and Berinert sales grew 6%.

Headcount: 24,660
Revenues: $13,310 (+31%)
Net Income: $7,250 (+32%)
R&D: $1,232 (+22%)

Melbourne, Australia-based CSL develops and delivers innovative medicines that help people with serious and life-threatening conditions through three businesses: CSL Behring, a global biotherapeutics leader; CSL Seqirus, a leading influenza vaccine provider; and the recently acquired CSL Vifor, a global partner for pharmaceuticals and innovative therapies in iron deficiency and nephrology.

Revenue for fiscal year 2023 was $13.31 billion, up 31% when compared to the prior comparable period, delivered against a challenging operating environment. In particular, the CSL Behring business rebounded strongly driven by growth in immunoglobulin sales and record plasma collections.

Early 2023 was marked by a major leadership transition as Paul Perreault retired from his role as CEO and managing director after 10 years in the position. Dr. Paul McKenzie was appointed as the new chief executive and managing director in March 2023, bringing more than 30 years of leadership experience in the global biotechnology industry, including his time at CSL as the chief operating officer.

In March 2023, CSL celebrated the opening of a new plasma fractionation facility in Marburg, Germany, a $470 million project that took five years to construct. With optimized process flows, modern technologies and automation, the new fractionation facility quadruples the current capacity.

In June 2023, the first patient received FDA approved gene therapy Hemgenix for hemophilia B in the U.S. In March 2024, the FDA approved Vafseo tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.

Most recently, in June, CSL Seqirus was selected by the Health Emergency Preparedness and Response Authority (HERA), part of the European Commission (EC), to provide 665,000 pre-pandemic vaccine doses for fifteen EU and EEA member states as well as to the “Union Civil Protection Mechanism.”

Headcount: 25,000
Revenues: $8,951
Net Income: $2,117
R&D: $857
*CSL does not report annual results until 30 June, so data is estimated.

TOP SELLING DRUGS

Headcount: 10,500
Bio/Pharma Revenue: $4,550 (10%)
Total Revenues: $4,747 (11%)
Net Income: $1,009 (8%)
R&D Budget: $364 (13%)

Top Selling Drugs

Account for 61% of total biopharma sales, down from 63% in previous year.

NOTE: Fiscal year ends June 30, so these results are based on previous fiscal year, ending June 30, 2011

NOTE: Australian dollar appreciated 4% from year to year, creating  jumps in results in USD

Headcount: 10,000
Pharma Revenues: $3,930 (23%/4%*)
Total Revenues: $4,082 (8%/-8%*)
Net Income: $929 (8%/-8%*)
R&D Budget: $280 (20%/2%*)

* Converted at avg. exch. rate / based on reported currency (AUD)

Fiscal year ends June 30, so these results are based on previous fiscal year, ending June 30, 2010

Australian dollar appreciated 17% from year to year, creating extreme jumps in results in USD

Top-Selling Drugs in 2010

Account for 56% of total biopharma sales, same as previous year..

Previous Profile: Biogen Idec. // Next Profile: Genzyme